公开(公告)号：US20130096155A1

公开(公告)日：2013-04-18

申请号：US13605329

申请日：2012-09-06

申请人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

发明人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

IPC分类号： C07D471/04

CPC分类号： C07D471/04

摘要： The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

摘要翻译： 本发明提供具有脯氨酰羟化酶抑制作用和促红细胞生成素产生诱导能力的三唑并吡啶化合物。 本发明涉及由下式[I]表示的化合物：其中每个符号如说明书中所定义，或其药学上可接受的盐，或其溶剂合物，以及脯氨酰羟化酶抑制剂或促红细胞生成素生产诱导 含有该化合物的试剂。 本发明的化合物显示出脯氨酰羟化酶抑制作用和促红细胞生成素的产生诱导能力，并且可用作用于促进红细胞生成素产生减少引起的各种疾病和病症（疾病）的预防或治疗剂。

公开(公告)号：US20130085132A1

公开(公告)日：2013-04-04

申请号：US13599665

申请日：2012-08-30

申请人： Tomoya MIURA ,  Yosuke OGOSHI ,  Kazuhito UEYAMA ,  Dai MOTODA ,  Toshihiko IWAYAMA ,  Koichi SUZAWA ,  Hironobu NAGAMORI ,  Hiroshi UENO ,  Akihiko TAKAHASHI ,  Kazuyuki SUGIMOTO

发明人： Tomoya MIURA ,  Yosuke OGOSHI ,  Kazuhito UEYAMA ,  Dai MOTODA ,  Toshihiko IWAYAMA ,  Koichi SUZAWA ,  Hironobu NAGAMORI ,  Hiroshi UENO ,  Akihiko TAKAHASHI ,  Kazuyuki SUGIMOTO

IPC分类号： C07D403/12 ,  C07D405/12 ,  C07D403/14 ,  C07D413/12 ,  C07D409/12 ,  C07D401/12 ,  C07D405/14

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12

摘要： The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

公开(公告)号：US20110077267A1

公开(公告)日：2011-03-31

申请号：US12837679

申请日：2010-07-16

申请人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

发明人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

IPC分类号： A61K31/437 ,  C07D471/04 ,  A61P7/06

CPC分类号： C07D471/04

摘要： The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

摘要翻译： 本发明提供具有脯氨酰羟化酶抑制作用和促红细胞生成素产生诱导能力的三唑并吡啶化合物。 本发明涉及由下式[I]表示的化合物：其中每个符号如说明书中所定义，或其药学上可接受的盐，或其溶剂合物，以及脯氨酰羟化酶抑制剂或促红细胞生成素生产诱导 含有该化合物的试剂。 本发明的化合物显示脯氨酰羟化酶抑制作用和促红细胞生成素的产生诱导能力，并且可用作用于促进红细胞生成素产生减少引起的各种疾病和病症（疾病）的预防或治疗剂。

公开(公告)号：US08283465B2

公开(公告)日：2012-10-09

申请号：US12837679

申请日：2010-07-16

申请人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

发明人： Ikuo Mitani ,  Yosuke Ogoshi ,  Takuya Matsui ,  Masahiro Yokota ,  Masakazu Terashita ,  Dai Motoda ,  Kazuhito Ueyama ,  Hiroyuki Abe ,  Takahiro Hotta ,  Takashi Ito

IPC分类号： C07D345/00

CPC分类号： C07D471/04

摘要： The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

摘要翻译： 本发明提供具有脯氨酰羟化酶抑制作用和促红细胞生成素产生诱导能力的三唑并吡啶化合物。 本发明涉及由下式[I]表示的化合物：其中每个符号如说明书中所定义，或其药学上可接受的盐，或其溶剂合物，以及脯氨酰羟化酶抑制剂或促红细胞生成素生产诱导 含有该化合物的试剂。 本发明的化合物显示脯氨酰羟化酶抑制作用和促红细胞生成素的产生诱导能力，并且可用作用于促进红细胞生成素产生减少引起的各种疾病和病症（疾病）的预防或治疗剂。

公开(公告)号：US08846746B2

公开(公告)日：2014-09-30

申请号：US13599665

申请日：2012-08-30

申请人： Tomoya Miura ,  Yosuke Ogoshi ,  Kazuhito Ueyama ,  Dai Motoda ,  Toshihiko Iwayama ,  Koichi Suzawa ,  Hironobu Nagamori ,  Hiroshi Ueno ,  Akihiko Takahashi ,  Kazuyuki Sugimoto

发明人： Tomoya Miura ,  Yosuke Ogoshi ,  Kazuhito Ueyama ,  Dai Motoda ,  Toshihiko Iwayama ,  Koichi Suzawa ,  Hironobu Nagamori ,  Hiroshi Ueno ,  Akihiko Takahashi ,  Kazuyuki Sugimoto

IPC分类号： A01N43/56 ,  A61K31/415 ,  C07D405/14 ,  C07D403/14 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12 ,  C07D413/12 ,  C07D405/12

CPC分类号： C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12

摘要： The present invention provides a pyrazole compound of the following general Formula [Ib] having SGLT1 inhibitory activity, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and its pharmaceutical use: wherein each symbol is the same as defined in the description.

摘要翻译： 本发明提供具有SGLT1抑制活性的以下通式[Ib]的吡唑化合物或其药学上可接受的盐，包含其的药物组合物及其药物用途：其中每个符号与描述中定义的相同 。